Trevi Therapeutics
- Market cap
- 1.87B
- P/E (TTM)i
- -37.54
- P/Bi
- 5.82
- EPSi
- -0.32
- Div yieldi
- 0.00%
- 52W posi
- 35%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Trevi Therapeutics closed at 13.14, down 0.30%. At current prices, the business is worth about 1.87B, the #2810 most valuable US-listed company we track. Wall Street's 10-analyst consensus lands on Buy, with a price target averaging 29.00 (+121% from here). Against a 52-week band of 9.28-20.22, the shares are currently 35% of the way up.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 1 week.
- Its last 6 Sell calls were actually followed by a +21% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +2.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 8.5% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 13.18
- Open
- 12.94
- Day range
- 12.84 - 13.53
- Avg price
- 13.19
- Volume
- 5.37M
- Turnover
- 70.78M
- Turnover ratei
- 4.54%
- Volume ratioi
- 1.77
- Amplitudei
- 5.23%
- 52-week rangei
- 9.28 - 20.22
Valuation
- P/Ei
- -41.06
- P/E (TTM)i
- -37.54
- P/Bi
- 5.82
- EPSi
- -0.32
- Book value / shi
- 2.26
- Net profit
- -45.59M
- Net assets
- 321.57M
Share structure
- Market cap
- 1.87B
- Float capi
- 1.55B
- Shares out
- 142.48M
- Float sharesi
- 118.32M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-05-07
35.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-9.66M net over the window
Short interest
- Shares short
- 12.07M
- % of floati
- 8.47%
- Days to coveri
- 8.79
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Trevi Therapeutics (TRVI)?
Trevi Therapeutics last traded at 13.14. The quote on this page refreshes every few seconds while US markets are open.
What is Trevi Therapeutics's market cap?
About 1.87B.
What is the P/E ratio of Trevi Therapeutics?
The trailing twelve-month P/E is -37.54. The Valuation tab shows it against the stock's own five-year range.
Does Trevi Therapeutics pay a dividend?
Trevi Therapeutics does not currently pay a regular dividend.
Is Trevi Therapeutics a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 29.00, which implies 120.7% upside from the current price. This is not investment advice.
What is Trevi Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Trevi Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 04:33:25 · For reference only, not investment advice and not tailored to your situation.